$PACB News

PacBio Cuts Outlook as SPRQ-Nx Transition Slows, Targets 2028 Cash-Flow Positivity

5 Must-Read Analyst Questions From PacBio’s Q2 Earnings Call

Pacific Biosciences of California, Inc. 2026 Q2 - Results - Earnings Call Presentation

Pacific Biosciences of California Q2 Earnings Call Highlights

Pacific Biosciences: It's Only Getting Worse

Pacific Biosciences of California, Inc. (PACB) Q2 2026 Earnings Call Transcript

Pacific Biosciences (NASDAQ:PACB) Shares Drop After Q2 Revenue Miss

Pacific Biosciences of California (PACB) Reports Q2 Loss, Lags Revenue Estimates

PacBio (NASDAQ:PACB) Reports Sales Below Analyst Estimates In Q2 CY2026 Earnings

PacBio Appoints Mark Van Oene as President and Chief Executive Officer

PacBio Announces Second Quarter 2026 Financial Results

Pacific Biosciences Of California Approves Restructuring Plan To Align With Strategic Initiatives; Restructuring To Reduce Workforce By About 8%; Expects $30M-$40M Annualized Operating Expense Reduction By End Of 2027; Estimates $2M Pre-Tax Charges For Reduction In Force

Pacific Biosciences Lowers FY2026 Sales Guidance from $165.000M-$175.000M to $155.000M-$165.000M vs $166.790M Est

Pacific Biosciences of California Appoints Mark Van Oene As President, CEO, Effective Immediately, Succeeding Christian Henry

Pacific Biosciences Q2 Adj. EPS $(0.14) Misses $(0.13) Estimate, Sales $39.007M Miss $40.067M Estimate

PacBio Announces Faster Runs, Up to 50% More HiFi Data, and New Compliance Controls for the Vega system

Pacific Biosciences of California, Inc. Q2 2026 Earnings Call Summary

Pacific Biosciences of California (PACB) Laps the Stock Market: Here's Why

PacBio to Participate in the Canaccord Genuity 46th Annual Growth Conference

Here's Why Pacific Biosciences of California (PACB) Fell More Than Broader Market